22 October 2024 The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
Roche has been granted US Food and Drug Administration approval for a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab), plus chemo, for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). 7 December 2018
An exclusive Expert View column written for The Pharma Letter by Thomas Cueni, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) director general and co-chair of the APEC Biopharmaceutical Working Group on Ethics. 6 December 2018
The most important M&A news of the month was arguably the giant step taken by Japanese drugmaker Takeda towards taking over rare diseases specialist Shire in the year's biggest deal, with shareholders voting in favor of the acquisition. 6 December 2018
A more robust approach will be taken to enforcing intellectual property (IP) in China, new punishments announced by the National Development and Reform Commission show. 6 December 2018
A new survey from NORC at the University of Chicago finds that two-thirds of adults in the USA do not intend to get the flu vaccine this season. 6 December 2018
Shionogi is the sole investor in the Series A funding round of Vast Therapeutics, a privately-owned US company that focuses on research and development of inhaled antimicrobial drugs enabling spontaneous and controlled nitric oxide release. 6 December 2018
An analysis from cryptocurrency broker GlobalBlock outlines the potential value of blockchain to the pharmaceutical industry, calling the two “an almost perfect match.” 6 December 2018
US biopharmaceutical services firm Parexel has entered into a new collaboration with US pharma major Eli Lilly to launch a clinical research learning and development program in China. 6 December 2018
Roche’s Kadcyla (trastuzumab emtansine) has passed a Phase III test comparing the antibody-drug conjugate (ADC) with Herceptin (trastuzumab) as a therapy for certain breast cancers. 6 December 2018
The well-documented case of Medicaid being overcharged over EpiPen (epinephrine), the emergency allergy treatment from Mylan, has led two Senators to propose a bipartisan bill. 5 December 2018
Drug-making is sometimes pictured as one of the last surviving “traditional” industries, successfully resisting waves of change that have overtaken other businesses. 5 December 2018
Today the UK government has published the second Life Sciences Sector Deal, the extension of a previous set of deals announced alongside the UK’s Industrial Strategy in November 2017. 5 December 2018
Approval by the US Food and Drug Administration of a highly potent opioid has garnered national attention and criticism from physicians, politicians, and others concerned about the increasing numbers of Americans dying from opioid overdoses, notes Dr Nicola Davies in her latest exclusive blog for The Pharma Letter. 5 December 2018
Janssen Pharmaceutical, the pharma business of US healthcare company Johnson & Johnson, has announced positive Phase III data for Darzalex (daratumumab) at the annual meeting of the American Society of Hematology. 5 December 2018
Leverkusen's Bayer has announced new growth and margin targets, including overall sales growth of approximately 4% in 2019 and an annual average rate of 4-5% in the following years, through to 2022. 5 December 2018
The worth of extended-release treatments for opioid use disorder has been questioned in analysis from the Institute for Clinical and Economic Review (ICER). 4 December 2018
Finnish drugmaker Orion Corp and Swiss pharma giant Novartis have agreed that Novartis will return the sales and distribution rights in certain European countries for Parkinson's disease drug Stalevo (levodopa, carbidopa, entacapone). 4 December 2018
London-listed drugmaker GlaxoSmithKline has divested its Horlicks brand and other consumer healthcare nutrition brands to Unilever, as part of a previously-announced strategic overhaul. 4 December 2018
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain. 21 October 2024
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.